Drug major Lupin has received the USFDA approval to market a generic version of ViiV Healthcare’s Epivir tablets, used for treating HIV infection, in the American market.
The Mumbai-based firm has received final approval from the US Food and Drug Administration (USFDA) for its Lamivudine tablets in strengths of 150 mg and 300 mg, Lupin Ltd said in a statement.
Lupin Pharmaceuticals Inc (LPI), the company’s US subsidiary, would commence marketing the product shortly, it added.
Epivir tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection.
According to IMS MAT September 2014 sales data, Epivir tablets had annual US sales of $39.7 million.
Lupin shares ended at Rs 1,406.40, up 0.26 per cent over the previous close.